期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Evolution of Viral Load in Patients Infected with HIV-1 at Point G University Hospital
1
作者 A. Maiga D. Kone +6 位作者 D. M. Coulibaly Ag M. Baraika A. Traore S. S. Diakite I. I. Maiga I. Konate A. I. Maiga 《Open Journal of Medical Microbiology》 2024年第1期66-76,共11页
Introduction: HIV, the human immunodeficiency virus, is the etiological agent of acquired immunodeficiency syndrome (AIDS). The aim of this study was to assess the evolution of the viral load in patients under treatme... Introduction: HIV, the human immunodeficiency virus, is the etiological agent of acquired immunodeficiency syndrome (AIDS). The aim of this study was to assess the evolution of the viral load in patients under treatment. Methodology: This was a study carried out from July 2017 to June 2022 at the Point G University Hospital laboratory. The determination of the viral load of patients was carried out by PCR on the ABOTT M2000sp/rt platform. Results: A total of 129 patients infected with HIV-1, aged 19 to 72 years with a mean age of 40.05 years ± 10.71;all on antiretroviral chemotherapy. The female gender predominated among our patients. The most common treatment regimen was 2INTI + 1INNTI with 72.9% followed by 2INTI + 1INI with 13.2%. As for the combinations of molecules, the combination TDF + 3TC + EFV and TDF + 3TC + DTG predominated, respectively 65.1% and 13.2%. 89.9% of our patients had undetectable viremia after 12 months of treatment (p < 0.005) with an average viral load which had evolved from 681315.65 copies/ml ± 1616908.484 to M0 at 5742.36 copies /ml ± 35756.883 at M12 (p Conclusion: Generally speaking, antiretroviral treatment had contributed to controlling viral loads, however the therapeutic combination TDF + 3TC + DTG had made it possible to obtain more patients with undetectable viremia instead. 展开更多
关键词 hiv-1 TREATMENT viral load Point G University Hospital
下载PDF
Xpert HIV-1病毒载量检测系统用于HIV-1病毒载量检测的临床价值 被引量:2
2
作者 杨坤 王静 +7 位作者 李同心 李俊刚 李梅 罗福龙 邓仁麑 刘敏 聂晓平 陈耀凯 《中国感染与化疗杂志》 CAS CSCD 北大核心 2020年第1期55-59,共5页
目的探讨Xpert HIV-1病毒载量(Xpert HIV-1 VL)检测用于HIV-1病毒载量检测的临床价值。方法采用Xpert HIV-1 VL和Abbott m2000 Real Time检测系统(Abbott m2000)同时检测191份血浆样本的HIV-1病毒载量。采用符合率、卡方检验和Kappa值... 目的探讨Xpert HIV-1病毒载量(Xpert HIV-1 VL)检测用于HIV-1病毒载量检测的临床价值。方法采用Xpert HIV-1 VL和Abbott m2000 Real Time检测系统(Abbott m2000)同时检测191份血浆样本的HIV-1病毒载量。采用符合率、卡方检验和Kappa值等统计分析两种检测方法定性检测结果的一致性,采用相关性、回归分析和Bland-Altman模型等统计分析两种检测方法定量检测结果的一致性。结果两种检测方法的阳性符合率、阴性符合率和总符合率均为100%,两种方法检测结果一致性分析的Kappa值为1.00(P<0.001);两种方法检测结果的相关系数为0.9576,回归分析表现出较高的相关性(R2=0.9170),Bland-Altman模型分析显示两种方法检测有95.3%(164/172)的样本在95%一致性界限内。结论Xpert HIV-1 VL用于检测HIV-1 RNA具有很高的灵敏度、准确性和稳定性,且操作简单、方便、安全,适合临床用于对HIV-1患者血浆样本中HIV-1 RNA的检测。 展开更多
关键词 人类免疫缺陷病毒1 病毒载量 xpert hiv-1病毒载量检测 Abbott m2000 Real Time系统 对比研究
下载PDF
Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad
3
作者 Chatté Adawaye Kamangu Erick +5 位作者 Soudy I. Djibrine Aoudalkarim Moussa Chahad Ali Mahamat Moussa Tchombou HZ Bertin Vaira Dolores Moutschen Michel 《World Journal of AIDS》 2014年第3期301-305,共5页
Contexte:?The fight against HIV/AIDS epidemics is one of the greatest challenges of this century. The epidemic affects generally under-developed countries, and Sub-Saharan Africa are the most concerned. The combined m... Contexte:?The fight against HIV/AIDS epidemics is one of the greatest challenges of this century. The epidemic affects generally under-developed countries, and Sub-Saharan Africa are the most concerned. The combined marketed form known as Triomune was used as first-line treatment in several sub-Saharan African Countries (60% of VIH infected people), including Chad. However, no evaluation has been done for that treatment in the country. Objective: To evaluate the efficacy and safety immuno-virological of Triomune at the General Hospital in N’Djamena/Chad. Methods: 48 HIV-1 positive patients eligible for ARV treatment were enrolled in our study, and they have been then followed for 8 months. We have measured in these patients the CD4 cell count before treatment and at the 8th month of treatment. After 8 months of treatment, we have also evaluated the Lymphocyte T CD4 and the plasma viral load (VL). Comparisons of means of CD4 lymphocytes and plasma CV (≥1000 copies/ml) were used to define treatment failure.?Results:?48 patients were under Triomune regime. The average CD4 count was decreased from 462 ± 179.22 [56 - 981] cells/mm3?before treatment to 327.23 ± 153.77 [10 - 1008] cells/mm3?at the 8th month of treatment. The mean plasma viral load for patients was 66008.62 copies/ml. The failure rate to Triomune was 43.75% (21/48).?Conclusion:?Aside from the side effects already described for Triomune, our study reveals a high treatment failure rate. Hence, there is the need of regular revisions of therapeutic regime administer in the first intention. 展开更多
关键词 Plasma viral load Triomune ANTIRETROviral Therapy Virological Failure ARVs hiv-1 First Line
下载PDF
Trends of HIV Viral Load in Patients under Combined Antiretroviral Treatment in Bangui, Central African Republic
4
作者 Yawo Tufa Nyasenu Alain Farra +12 位作者 Serge Ghislain Djorie Brice Martial Yambiyo Alexandre Manirakiza Gilles Stephane Ngaya Sandrine Moussa Pulcherie Pelembi Davy Martial Golongba Aubin Bere Rodolphe Mambely-Nzako Marie-Joelle Mandeng Alain Berlioz-Arthaud Pierre-Alain Rubbo Jean-Pierre Lombart 《World Journal of AIDS》 2018年第2期53-62,共10页
Background: The success of antiretroviral therapy requires better virological monitoring. We described the virological profile of patients on combined antiretroviral therapy (cART) for HIV/AIDS in Bangui, Central Afri... Background: The success of antiretroviral therapy requires better virological monitoring. We described the virological profile of patients on combined antiretroviral therapy (cART) for HIV/AIDS in Bangui, Central African Republic (CAR). Methods: In this prospective cohort study of patients who had been on combined antiretroviral therapy treatment (cART) for at least 12 months in Bangui, only one HIV plasma viral load per patient was realized at the Institut Pasteur of Bangui, between April 4th and November 28th, 2017. Sociodemographic and biological data were collected. Blood samples were taken for viral load. The biocentric generic human immunodeficiency virus (HIV) load test was used to quantify a ribonucleic acid (RNA) HIV-1. Data were analyzed with Stata software version 14. Chi-squared test was used to analyse viral load according to sex and age. The level of significance was set at P ≤ 0.05. Results: A total of 3569 patients were recruited, with a mean age of 40 years (median, 42 years;range, 1 - 84), patients aged 40 - 49 predominating (34.2%). The sex ratio was 0.4. No virus was detectable in plasma from 49.2% of patients, while 42.4% had virological failure (viral load, ≥1000 copies/mL) according to WHO criteria. The risk for virological failure decreased with age (P = 0.001) and was higher among females than males (P = 0.001). Conclusions: The rate of virological failure among patients on cART is very high in the CAR, despite the availability of and access to monitoring of HIV plasma viral load in Bangui. Therefore, adherence to treatment should be evaluated and reinforced in Bangui, CAR. 展开更多
关键词 Plasma viral load FAILURE hiv-1 Bangui CAR
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部